Christopher A. Cassa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Christopher A. Cassa has a total of 384 co-authors. Here are the top co-authors by number of shared publications:
- Richard I. Sherwood
Division of Genetics, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School
7 shared publications Tian Yu
Brigham and Women’s Hospital / Harvard Medical School, Boston, MA, USA
7 shared publicationsJames D. Fife
Division of Genetics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
6 shared publications- Kenneth D. Mandl
Boston Children's Hospital
6 shared publications - Daniel M. Jordan
Icahn School of Medicine at Mount Sinai
5 shared publications Matthew Lebo
Mass General Brigham Personalized Medicine, Boston, MA, USA
5 shared publications
Latest Publications
- 27 October 2026
- Published by Wolters Kluwer Health in Circulation
- Vol. 154 (17) , 1718-1734
LDLR Variant Classification Through Activity-Normalized Prime Editing Screening
BACKGROUND: Inherited variants in the LDL (low-density lipoprotein) receptor ( LDLR ) gene are the most common cause of familial hypercholesterolemia, significantly increasing coronary artery disease risk. Early identification of pathogenic LDLR variants enables prompt lipid-lowering therapy and cascade testing of at-risk relatives; however, most LDLR variants observed in the population have uncertain or absent clinical classifications, leaving many patients without actionable information. METHODS: We developed the first activity-normalized prime editing screening pipeline to measure the impact of 5184 LDLR coding variants on LDL-cholesterol (LDL-C) uptake. Each prime editing guide RNA is paired with a genotypic outcome reporter to correct for variable editing efficiency, overcoming a key limitation of previous pooled genome editing screens. A statistical framework further improves variant effect estimates by jointly analyzing all missense variants at each amino acid position. RESULTS: We show that prime editing of the reporter construct correlates with endogenous variant installation frequency, validating the activity normalization approach. The resulting scores capture a continuous spectrum of functional effects, robustly separate pathogenic versus benign ClinVar variants, and show concordance with LDL-C levels in UK Biobank participants. We calibrate functional evidence strengths to the American College of Medical Genetics and Genomics/AMP variant interpretation framework, enabling integration into a clinical variant classification workflow. By combining functional, computational, population, and contextual evidence, 322 of 434 LDLR variants currently classified as variants of uncertain significance, conflicting, or absent from ClinVar appear to meet evidence thresholds for reclassification and can be prioritized for expert review, substantially expanding the pool of actionable variant classifications. The screen also reveals a cluster of gain-of-function variants in LDLR class A repeat 5, at least some of which enhance LDL-C uptake through increased apolipoprotein B interaction, with implications for therapeutic genome editing. Last, prime editing uniquely detects splice-altering coding variants missed by cDNA-based screens and pathogenicity predictors, revealing an advantage of endogenous variant installation. CONCLUSIONS: Altogether, activity-normalized prime editing provides a scalable framework for LDLR variant classification that substantially expands the proportion of variants with evidence for genetic diagnosis and reveals novel biology with therapeutic relevance.
- 27 October 2026
- Published by Wolters Kluwer Health in Circulation
- Vol. 154 (17) , 1718-1734
LDLR Variant Classification Through Activity-Normalized Prime Editing Screening
BACKGROUND: Inherited variants in the LDL (low-density lipoprotein) receptor ( LDLR ) gene are the most common cause of familial hypercholesterolemia, significantly increasing coronary artery disease risk. Early identification of pathogenic LDLR variants enables prompt lipid-lowering therapy and cascade testing of at-risk relatives; however, most LDLR variants observed in the population have uncertain or absent clinical classifications, leaving many patients without actionable information. METHODS: We developed the first activity-normalized prime editing screening pipeline to measure the impact of 5184 LDLR coding variants on LDL-cholesterol (LDL-C) uptake. Each prime editing guide RNA is paired with a genotypic outcome reporter to correct for variable editing efficiency, overcoming a key limitation of previous pooled genome editing screens. A statistical framework further improves variant effect estimates by jointly analyzing all missense variants at each amino acid position. RESULTS: We show that prime editing of the reporter construct correlates with endogenous variant installation frequency, validating the activity normalization approach. The resulting scores capture a continuous spectrum of functional effects, robustly separate pathogenic versus benign ClinVar variants, and show concordance with LDL-C levels in UK Biobank participants. We calibrate functional evidence strengths to the American College of Medical Genetics and Genomics/AMP variant interpretation framework, enabling integration into a clinical variant classification workflow. By combining functional, computational, population, and contextual evidence, 322 of 434 LDLR variants currently classified as variants of uncertain significance, conflicting, or absent from ClinVar appear to meet evidence thresholds for reclassification and can be prioritized for expert review, substantially expanding the pool of actionable variant classifications. The screen also reveals a cluster of gain-of-function variants in LDLR class A repeat 5, at least some of which enhance LDL-C uptake through increased apolipoprotein B interaction, with implications for therapeutic genome editing. Last, prime editing uniquely detects splice-altering coding variants missed by cDNA-based screens and pathogenicity predictors, revealing an advantage of endogenous variant installation. CONCLUSIONS: Altogether, activity-normalized prime editing provides a scalable framework for LDLR variant classification that substantially expands the proportion of variants with evidence for genetic diagnosis and reveals novel biology with therapeutic relevance.
- Open Access
- 19 May 2026
- Published by Springer Nature in Genome Medicine
- Vol. 18 (1)
From text to translation: using language models to prioritize variants for clinical review
Despite rapid advances in genomic sequencing, most rare coding variants remain insufficiently characterized for clinical use, limiting the potential of personalized medicine. When classifying whether a variant is pathogenic, clinical labs adhere to diagnostic guidelines that integrate many forms of evidence, including case data, computational predictions, and functional screening data. While a great deal of clinical evidence has been curated for many variants, the majority still cannot be definitively classified as 'pathogenic' or 'benign', and thus persist as 'Variants of Uncertain Significance' (VUS). Variant Curation Expert Panels (VCEPs) are tasked with analyzing the available evidence for each variant to reach a classification. To make use of previously curated evidence, we processed over 2.3 million free-text variant summaries from ClinVar, employing sentence-level classification to restrict to sentences that contain different forms of evidence, and removing uninformative or similar summaries. We then used labeled text summaries to train ClinVar-BERT, a model that can discern evidence of pathogenicity or benignity within variant text summaries. We validated ClinVar-BERT model predictions for variant summaries that are classified as uncertain using variants curated by expert panels, orthogonal functional screening data, and computational predictions. ClinVar-BERT model predictions of VUS had significantly different estimates of functional impact in clinically actionable genes, including BRCA1 (p = [Formula: see text]), TP53 (p = [Formula: see text]), and PTEN (p = [Formula: see text]) with an AUROC = 0.927 when classifying whether variants are damaging or are expected to retain function. Similarly, ClinVar-BERT model predictions of VUS had significantly different AlphaMissense computational scores: BRCA1 (p = [Formula: see text]), TP53 (p = [Formula: see text]), and PTEN (p = [Formula: see text]). In genes screened for secondary findings or included on ClinGen expert panels, ClinVar-BERT prioritizes 7,644 variants for expert review, where 2 or more clinical summaries related to the same VUS were model-predicted to contain pathogenic evidence, and 7,042 variants with 2 or more summaries predicted to contain benign evidence. This would result in the average VCEP having 143 variants prioritized for review, ranging from 8 to 907 variants across VCEPs. These findings suggest that ClinVar-BERT can discern evidence from diagnostic reports, useful for prioritizing variants for re-assessment by expert curation panels.
- 19 May 2026
- Published by Springer Nature in Genome Medicine
- Vol. 18 (1)
Open AccessFrom text to translation: using language models to prioritize variants for clinical review
Despite rapid advances in genomic sequencing, most rare coding variants remain insufficiently characterized for clinical use, limiting the potential of personalized medicine. When classifying whether a variant is pathogenic, clinical labs adhere to diagnostic guidelines that integrate many forms of evidence, including case data, computational predictions, and functional screening data. While a great deal of clinical evidence has been curated for many variants, the majority still cannot be definitively classified as 'pathogenic' or 'benign', and thus persist as 'Variants of Uncertain Significance' (VUS). Variant Curation Expert Panels (VCEPs) are tasked with analyzing the available evidence for each variant to reach a classification. To make use of previously curated evidence, we processed over 2.3 million free-text variant summaries from ClinVar, employing sentence-level classification to restrict to sentences that contain different forms of evidence, and removing uninformative or similar summaries. We then used labeled text summaries to train ClinVar-BERT, a model that can discern evidence of pathogenicity or benignity within variant text summaries. We validated ClinVar-BERT model predictions for variant summaries that are classified as uncertain using variants curated by expert panels, orthogonal functional screening data, and computational predictions. ClinVar-BERT model predictions of VUS had significantly different estimates of functional impact in clinically actionable genes, including BRCA1 (p = [Formula: see text]), TP53 (p = [Formula: see text]), and PTEN (p = [Formula: see text]) with an AUROC = 0.927 when classifying whether variants are damaging or are expected to retain function. Similarly, ClinVar-BERT model predictions of VUS had significantly different AlphaMissense computational scores: BRCA1 (p = [Formula: see text]), TP53 (p = [Formula: see text]), and PTEN (p = [Formula: see text]). In genes screened for secondary findings or included on ClinGen expert panels, ClinVar-BERT prioritizes 7,644 variants for expert review, where 2 or more clinical summaries related to the same VUS were model-predicted to contain pathogenic evidence, and 7,042 variants with 2 or more summaries predicted to contain benign evidence. This would result in the average VCEP having 143 variants prioritized for review, ranging from 8 to 907 variants across VCEPs. These findings suggest that ClinVar-BERT can discern evidence from diagnostic reports, useful for prioritizing variants for re-assessment by expert curation panels.
- Open Access
Language models reveal evidence gaps in variants of uncertain significance
Background: Most rare coding variants in monogenic disease genes remain classified as Variants of Uncertain Significance (VUS), limiting their use in clinical care. Many variant classifications have been submitted to ClinVar, often with rich free-text summaries of the evidence underlying each classification. These narratives are not standardized and are difficult to mine systematically, making it challenging to identify variants that might be reclassified as new evidence becomes available. Methods: We developed a two-stage language-model pipeline that (i) detects whether functional, population, or computational evidence is described in ClinVar and ClinGen variant summaries, and (ii) classifies whether it is evidence of pathogenicity or benignity. We first constructed Variant Evidence Text Annotations (VETA), a dataset of 44,522 ACMG/AMP keyword-description pairs derived from 18,678 ClinVar and ClinGen variant summaries using an LLM-based consensus annotation procedure. We then fine-tuned BioBERT-large models for each evidence type and stage, and validated performance using independent ClinGen expert-curated summaries as well as orthogonal variant-level evidence, including functional screening, computational scores, and population estimates of disease impact. Results: Across evidence types, our models accurately identify whether functional, population, and computational evidence is present and whether it leans toward a pathogenic or benign impact. We find high agreement with ClinGen expert annotations and highly significant separation of validation scores between model-predicted benign and pathogenic groups (functional assays p = 8.13 × 10 − 30 , variant allele frequencies p = 4.11 × 10 − 22 , computational predictions p < 8.88 × 10 − 16 ). We applied the full workflow to approximately 6,000 ClinVar VUS variants whose submission summaries lacked explicit functional or population evidence. By aggregating external functional, population, computational, and diagnostic evidence using the ACMG/AMP SVI point-based framework, we found that about 17% of these VUS meet quantitative thresholds for a likely benign or likely pathogenic classification, including 492 VUS in genes reviewed by ClinGen Variant Curation Expert Panels. Conclusions: Transforming unstructured variant summaries into a structured, evidence-type matrix enables scalable detection of evidence gaps, allowing for the systematic integration of new data sources, and prioritization of VUS that are most likely to be reclassified. This language model-enabled pipeline provides a generalizable digital approach to identify clinical evidence gaps as functional screens, biobank resources, and computational predictors continue to evolve.
Open AccessLanguage models reveal evidence gaps in variants of uncertain significance
Background: Most rare coding variants in monogenic disease genes remain classified as Variants of Uncertain Significance (VUS), limiting their use in clinical care. Many variant classifications have been submitted to ClinVar, often with rich free-text summaries of the evidence underlying each classification. These narratives are not standardized and are difficult to mine systematically, making it challenging to identify variants that might be reclassified as new evidence becomes available. Methods: We developed a two-stage language-model pipeline that (i) detects whether functional, population, or computational evidence is described in ClinVar and ClinGen variant summaries, and (ii) classifies whether it is evidence of pathogenicity or benignity. We first constructed Variant Evidence Text Annotations (VETA), a dataset of 44,522 ACMG/AMP keyword-description pairs derived from 18,678 ClinVar and ClinGen variant summaries using an LLM-based consensus annotation procedure. We then fine-tuned BioBERT-large models for each evidence type and stage, and validated performance using independent ClinGen expert-curated summaries as well as orthogonal variant-level evidence, including functional screening, computational scores, and population estimates of disease impact. Results: Across evidence types, our models accurately identify whether functional, population, and computational evidence is present and whether it leans toward a pathogenic or benign impact. We find high agreement with ClinGen expert annotations and highly significant separation of validation scores between model-predicted benign and pathogenic groups (functional assays p = 8.13 × 10 − 30 , variant allele frequencies p = 4.11 × 10 − 22 , computational predictions p < 8.88 × 10 − 16 ). We applied the full workflow to approximately 6,000 ClinVar VUS variants whose submission summaries lacked explicit functional or population evidence. By aggregating external functional, population, computational, and diagnostic evidence using the ACMG/AMP SVI point-based framework, we found that about 17% of these VUS meet quantitative thresholds for a likely benign or likely pathogenic classification, including 492 VUS in genes reviewed by ClinGen Variant Curation Expert Panels. Conclusions: Transforming unstructured variant summaries into a structured, evidence-type matrix enables scalable detection of evidence gaps, allowing for the systematic integration of new data sources, and prioritization of VUS that are most likely to be reclassified. This language model-enabled pipeline provides a generalizable digital approach to identify clinical evidence gaps as functional screens, biobank resources, and computational predictors continue to evolve.
- Open Access
LDLR variant classification through activity-normalized prime editing screening
Background: Inherited variants in the LDL receptor (LDLR) gene are the most common cause of familial hypercholesterolemia (FH), significantly increasing coronary artery disease risk. Early identification of pathogenic LDLR variants enables prompt intervention with lipid-lowering therapies; however, the majority of LDLR variants observed in the population have uncertain or absent clinical classifications, limiting the potential to improve clinical management. Methods: We developed an innovative, activity-normalized prime editing screening pipeline to measure the impact of 5,184 LDLR coding variants on LDL-cholesterol (LDL-C) uptake. Through pairing a genotypic outcome reporter with every prime editing guide RNA (pegRNA), we adjust phenotypic measurements to account for variable editing efficiency, extending activity normalization to prime editing for the first time at this scale. Further, we use a statistical estimation approach that leverages measurements for all missense variants at a given position to denoise the resulting scores. Results: We show that prime editing-mediated reporter editing correlates with endogenous variant installation frequency, allowing activity normalization to improve imputation of LDLR variant effect. Our optimized prime editing assay identifies a broad, continuous spectrum of variant functional effects. We achieve robust separation of pathogenic vs. benign ClinVar variants and concordance between experimentally derived functional scores and LDL-C levels measured in UK Biobank participants. Further, when calibrating the strength of evidence provided by this functional screening data to align with the ACMG/AMP variant interpretation guidelines, and integrating additional sources of evidence, a majority of currently unclassified rare LDLR variants meet evidence thresholds for reclassification. We use the broad coverage of this screen to gain insight into how apolipoproteins bind to LDLR. In particular, we identify and characterize rare LDLR variants that enhance LDL-C uptake through increased interaction with apolipoprotein B. Finally, we compare prime editing-based functional scores with those derived from recent base editing and cDNA-based LDLR variant screens, showing that these approaches all show robust correlation with clinically observed LDL-C levels and computational scores, while prime editing identifies candidate splice-altering coding variants that are not modeled by cDNA screening. Conclusions: Altogether, our approach demonstrates the power of prime editing to significantly improve understanding of how variants in LDLR impact function and contribute to FH.
Open AccessLDLR variant classification through activity-normalized prime editing screening
Background: Inherited variants in the LDL receptor (LDLR) gene are the most common cause of familial hypercholesterolemia (FH), significantly increasing coronary artery disease risk. Early identification of pathogenic LDLR variants enables prompt intervention with lipid-lowering therapies; however, the majority of LDLR variants observed in the population have uncertain or absent clinical classifications, limiting the potential to improve clinical management. Methods: We developed an innovative, activity-normalized prime editing screening pipeline to measure the impact of 5,184 LDLR coding variants on LDL-cholesterol (LDL-C) uptake. Through pairing a genotypic outcome reporter with every prime editing guide RNA (pegRNA), we adjust phenotypic measurements to account for variable editing efficiency, extending activity normalization to prime editing for the first time at this scale. Further, we use a statistical estimation approach that leverages measurements for all missense variants at a given position to denoise the resulting scores. Results: We show that prime editing-mediated reporter editing correlates with endogenous variant installation frequency, allowing activity normalization to improve imputation of LDLR variant effect. Our optimized prime editing assay identifies a broad, continuous spectrum of variant functional effects. We achieve robust separation of pathogenic vs. benign ClinVar variants and concordance between experimentally derived functional scores and LDL-C levels measured in UK Biobank participants. Further, when calibrating the strength of evidence provided by this functional screening data to align with the ACMG/AMP variant interpretation guidelines, and integrating additional sources of evidence, a majority of currently unclassified rare LDLR variants meet evidence thresholds for reclassification. We use the broad coverage of this screen to gain insight into how apolipoproteins bind to LDLR. In particular, we identify and characterize rare LDLR variants that enhance LDL-C uptake through increased interaction with apolipoprotein B. Finally, we compare prime editing-based functional scores with those derived from recent base editing and cDNA-based LDLR variant screens, showing that these approaches all show robust correlation with clinically observed LDL-C levels and computational scores, while prime editing identifies candidate splice-altering coding variants that are not modeled by cDNA screening. Conclusions: Altogether, our approach demonstrates the power of prime editing to significantly improve understanding of how variants in LDLR impact function and contribute to FH.
- 15 July 2025
- Published by Elsevier in The American Journal of Human Genetics
- Vol. 112 (8) , 1805-1817
Extracting and calibrating evidence of variant pathogenicity from population biobank data
- 15 July 2025
- Published by Elsevier in The American Journal of Human Genetics
- Vol. 112 (8) , 1805-1817
Extracting and calibrating evidence of variant pathogenicity from population biobank data
- Open Access
From Text to Translation: Using Language Models to Prioritize Variants for Clinical Review
Backgrounds: Despite rapid advances in genomic sequencing, most rare genetic variants remain insufficiently characterized for clinical use, limiting the potential of personalized medicine. When classifying whether a variant is pathogenic, clinical labs adhere to diagnostic guidelines that comprehensively evaluate many forms of evidence including case data, computational predictions, and functional screening. While a substantial amount of clinical evidence has been developed for many of these variants, the majority cannot be definitively classified as ‘pathogenic’ or ‘benign’, and thus persist as ‘Variants of Uncertain Significance’ (VUS). Methods: We processed over 2.4 million plaintext variant summaries from ClinVar, employing sentence-level classification to remove content that does not contain evidence and removing uninformative or highly similar summaries. We then trained ClinVar-BERT to discern clinical evidence within these summaries by fine-tuning a BioBERT-based model with labeled records. Results: We validated ClinVar-BERT model predictions for variant summaries that are classified as uncertain (VUS) using orthogonal functional screening data. ClinVar-BERT significantly separated estimates of functional impact in clinically actionable genes, including BRCA1 (p = 1.90×10 − 20 ), TP53 (p = 1.14×10 − 47 ), and PTEN (p = 3.82 × 10 − 7 ) and achieved an AUROC of 0.927 when classifying whether variants result in loss of function or have uncertain effects. Conclusion: These findings suggest that ClinVar-BERT is capable of discerning evidence from diagnostic reports and can be useful for prioritizing variants for re-assessment by diagnostic laboratories and expert curation panels.
Open AccessFrom Text to Translation: Using Language Models to Prioritize Variants for Clinical Review
Backgrounds: Despite rapid advances in genomic sequencing, most rare genetic variants remain insufficiently characterized for clinical use, limiting the potential of personalized medicine. When classifying whether a variant is pathogenic, clinical labs adhere to diagnostic guidelines that comprehensively evaluate many forms of evidence including case data, computational predictions, and functional screening. While a substantial amount of clinical evidence has been developed for many of these variants, the majority cannot be definitively classified as ‘pathogenic’ or ‘benign’, and thus persist as ‘Variants of Uncertain Significance’ (VUS). Methods: We processed over 2.4 million plaintext variant summaries from ClinVar, employing sentence-level classification to remove content that does not contain evidence and removing uninformative or highly similar summaries. We then trained ClinVar-BERT to discern clinical evidence within these summaries by fine-tuning a BioBERT-based model with labeled records. Results: We validated ClinVar-BERT model predictions for variant summaries that are classified as uncertain (VUS) using orthogonal functional screening data. ClinVar-BERT significantly separated estimates of functional impact in clinically actionable genes, including BRCA1 (p = 1.90×10 − 20 ), TP53 (p = 1.14×10 − 47 ), and PTEN (p = 3.82 × 10 − 7 ) and achieved an AUROC of 0.927 when classifying whether variants result in loss of function or have uncertain effects. Conclusion: These findings suggest that ClinVar-BERT is capable of discerning evidence from diagnostic reports and can be useful for prioritizing variants for re-assessment by diagnostic laboratories and expert curation panels.
- Open Access
- 9 October 2024
- Published by Elsevier in Cell Genomics
- Vol. 4 (10) , 100667
FUSE: Improving the estimation and imputation of variant impacts in functional screening
- 9 October 2024
- Published by Elsevier in Cell Genomics
- Vol. 4 (10) , 100667
Open AccessFUSE: Improving the estimation and imputation of variant impacts in functional screening
- Open Access
Extracting and calibrating evidence of variant pathogenicity from population biobank data
Summary: Genomic medicine requires a robust evidence base of variant phenotypic impacts, which remains incomplete even in extensively studied monogenic disease genes. Here, we evaluated the broad potential of using population cohort data to identify evidence that can be used in variant assessment. Across 41 genes related to 18 clinically actionable monogenic phenotypes, we calculated variant-level odds ratios of disease enrichment using data from 469,803 UK Biobank participants. We found significant differences in odds ratio values between ClinVar-labeled pathogenic and benign variants in 11 phenotypes, spanning both common and rare disorders. To facilitate clinical translation, we calibrated the strength of evidence provided by variant-level odds ratios to align with American College of Medical Genetics and Genomics (ACMG/AMP) interpretation guidelines (PS4 criterion), and found that odds ratios may reach ‘moderate’, ‘strong’, or ‘very strong’ evidence, varying by phenotype and gene. Overall, we found that 2.6% (N = 12,350) of participants harbor a rare VUS with at least ‘moderate’ evidence of pathogenicity – an indication of potentially unrecognized disease risk. Finally, by incorporating computational and functional data alongside population-based odds ratios, we identified variants that met criteria for clinical reclassification. Notably, using this approach, we identified that 12.4% of rare VUS in LDLR seen in participants meet diagnostic criteria to be classified as likely pathogenic, demonstrating its potential to scale the reclassification of VUS. Highlights: We identify rare coding variants that alter risk across 41 genes related to 18 actionable phenotypes. We find enrichments of cases in variants of uncertain significance related to rare and common disorders. We calibrate the strength of biobank population evidence for use in sequence variant interpretation. We combine evidence to identify uncertain variants that can be reclassified as likely pathogenic.
Open AccessExtracting and calibrating evidence of variant pathogenicity from population biobank data
Summary: Genomic medicine requires a robust evidence base of variant phenotypic impacts, which remains incomplete even in extensively studied monogenic disease genes. Here, we evaluated the broad potential of using population cohort data to identify evidence that can be used in variant assessment. Across 41 genes related to 18 clinically actionable monogenic phenotypes, we calculated variant-level odds ratios of disease enrichment using data from 469,803 UK Biobank participants. We found significant differences in odds ratio values between ClinVar-labeled pathogenic and benign variants in 11 phenotypes, spanning both common and rare disorders. To facilitate clinical translation, we calibrated the strength of evidence provided by variant-level odds ratios to align with American College of Medical Genetics and Genomics (ACMG/AMP) interpretation guidelines (PS4 criterion), and found that odds ratios may reach ‘moderate’, ‘strong’, or ‘very strong’ evidence, varying by phenotype and gene. Overall, we found that 2.6% (N = 12,350) of participants harbor a rare VUS with at least ‘moderate’ evidence of pathogenicity – an indication of potentially unrecognized disease risk. Finally, by incorporating computational and functional data alongside population-based odds ratios, we identified variants that met criteria for clinical reclassification. Notably, using this approach, we identified that 12.4% of rare VUS in LDLR seen in participants meet diagnostic criteria to be classified as likely pathogenic, demonstrating its potential to scale the reclassification of VUS. Highlights: We identify rare coding variants that alter risk across 41 genes related to 18 actionable phenotypes. We find enrichments of cases in variants of uncertain significance related to rare and common disorders. We calibrate the strength of biobank population evidence for use in sequence variant interpretation. We combine evidence to identify uncertain variants that can be reclassified as likely pathogenic.
- 24 April 2024
- Published by Springer Nature in Nature Genetics
- Vol. 56 (5) , 925-937
Joint genotypic and phenotypic outcome modeling improves base editing variant effect quantification
CRISPR base editing screens enable analysis of disease-associated variants at scale; however, variable efficiency and precision confounds the assessment of variant-induced phenotypes. Here, we provide an integrated experimental and computational pipeline that improves estimation of variant effects in base editing screens. We use a reporter construct to measure guide RNA (gRNA) editing outcomes alongside their phenotypic consequences and introduce base editor screen analysis with activity normalization (BEAN), a Bayesian network that uses per-guide editing outcomes provided by the reporter and target site chromatin accessibility to estimate variant impacts. BEAN outperforms existing tools in variant effect quantification. We use BEAN to pinpoint common regulatory variants that alter low-density lipoprotein (LDL) uptake, implicating previously unreported genes. Additionally, through saturation base editing of LDLR, we accurately quantify missense variant pathogenicity that is consistent with measurements in UK Biobank patients and identify underlying structural mechanisms. This work provides a widely applicable approach to improve the power of base editing screens for disease-associated variant characterization.
- 24 April 2024
- Published by Springer Nature in Nature Genetics
- Vol. 56 (5) , 925-937
Joint genotypic and phenotypic outcome modeling improves base editing variant effect quantification
CRISPR base editing screens enable analysis of disease-associated variants at scale; however, variable efficiency and precision confounds the assessment of variant-induced phenotypes. Here, we provide an integrated experimental and computational pipeline that improves estimation of variant effects in base editing screens. We use a reporter construct to measure guide RNA (gRNA) editing outcomes alongside their phenotypic consequences and introduce base editor screen analysis with activity normalization (BEAN), a Bayesian network that uses per-guide editing outcomes provided by the reporter and target site chromatin accessibility to estimate variant impacts. BEAN outperforms existing tools in variant effect quantification. We use BEAN to pinpoint common regulatory variants that alter low-density lipoprotein (LDL) uptake, implicating previously unreported genes. Additionally, through saturation base editing of LDLR, we accurately quantify missense variant pathogenicity that is consistent with measurements in UK Biobank patients and identify underlying structural mechanisms. This work provides a widely applicable approach to improve the power of base editing screens for disease-associated variant characterization.
- 25 May 2023
- Published by Elsevier in The American Journal of Human Genetics
- Vol. 110 (6) , 940-949
Estimating clinical risk in gene regions from population sequencing cohort data
- 25 May 2023
- Published by Elsevier in The American Journal of Human Genetics
- Vol. 110 (6) , 940-949
Estimating clinical risk in gene regions from population sequencing cohort data